Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

ENDRA Life Sciences Adds Nexus 128+ to Their 3D Preclinical Photoacoustic CT Lineup

ENDRA Inc.
Posted on: 01 Sep 16

PR Newswire

ANN ARBOR, Mich., Sept. 1, 2016

ANN ARBOR, Mich., Sept. 1, 2016 /PRNewswire/ -- ENDRA Life Sciences today announced the launch of the Nexus 128+, adding to their preclinical photoacoustic computed tomography (CT) systems that leverage ENDRA's proprietary 3D imaging technology. "The Nexus 128+ now provides up to twice the photoacoustic sensitivity of our previous system, the Nexus 128, enabling improved quantitation of preclinical animal models," said Michael Thornton, ENDRA's Chief Technology Officer. ENDRA's preclinical photoacoustic CT scanners are used by global research scientists to quantify molecular probe uptake and tumor vasculature.

ENDRA will showcase the Nexus 128+ at the 2016 World Molecular Imaging Congress (WMIC) in New York, NY, September 7 – 10, 2016, Booth #513. The company will also highlight recent studies, including an application note that demonstrates dual probe, 4D imaging to quantify molecular probe tumor penetration. 

"The launch of the Nexus 128+ demonstrates ENDRA's ongoing commitment to developing leading-edge tools that enable researchers to study disease models with unparalleled quality and speed," said Francois Michelon, ENDRA's Chief Executive Officer.

About ENDRA 

ENDRA Life Science's mission is to bring new capabilities to ultrasound.

ENDRA's Photoacoustic solutions currently help global medical researchers screen and modify disease models with high image quality and volume scanning speed.  ENDRA has a global installed base of leading institutions using the Nexus 128 system, the only fully 3D photoacoustic imaging solution for imaging anatomy, physiology and labeled molecular targets.

ENDRA's Thermo-Acoustic technology is being developed to enable clinicians to use their existing ultrasound equipment to clearly visualize tissue function, composition, and monitor a variety of therapeutic interventions – at the point of care. This directly aligns with current healthcare trends to improve patient access, clinical effectiveness, safety and cost.

Logo - http://photos.prnewswire.com/prnh/20160520/370526LOGO  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endra-life-sciences-adds-nexus-128-to-their-3d-preclinical-photoacoustic-ct-lineup-300321461.html

SOURCE ENDRA Inc.

PR Newswire
www.prnewswire.com

Last updated on: 01/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.